Cytokind’s Published Phase 1 Trial Results in COVID: NB-UVB reduced 28-day mortality by 60%

Published Study In Multiple Sclerosis and Related Disorders Provides Further Evidence that NB-UVB Phototherapy is an Effective Immune-Calming Therapy